Spruce biosciences announces new corporate strategy and acquisition of tralesinidase alfa for the treatment of sanfilippo syndrome type b (mps iiib)

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (ta-ert) for the treatment of sanfilippo syndrome type b (mps iiib). “this is truly a transformative moment for spruce as we focus ou.
SPRB Ratings Summary
SPRB Quant Ranking